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Abstract
The cytoplasmic TRIM5a proteins of certain mammalian lineages efficiently recognize the incoming capsids of particular
retroviruses and potently restrict infection in a species-specific manner. Successful retroviruses have evolved capsids that
are less efficiently recognized by the TRIM5a proteins of the natural hosts. To address whether TRIM5a contributes to the
outcome of retroviral infection in a susceptible host species, we investigated the impact of TRIM5 polymorphisms in rhesus
monkeys on the course of a simian immunodeficiency virus (SIV) infection. Full-length TRIM5a cDNAs were derived from
each of 79 outbred monkeys and sequenced. Associations were explored between the expression of particular TRIM5 alleles
and both the permissiveness of cells to SIV infection in vitro and clinical sequelae of SIV infection in vivo. Natural variation in
the TRIM5a B30.2(SPRY) domain influenced the efficiency of SIVmac capsid binding and the in vitro susceptibility of cells
from the monkeys to SIVmac infection. We also show the importance in vivo of the interaction of SIVmac with different
allelic forms of TRIM5, demonstrating that particular alleles are associated with as much as 1.3 median log difference in set-
point viral loads in SIVmac-infected rhesus monkeys. Moreover, these allelic forms of TRIM5 were associated with the extent
of loss of central memory (CM) CD4+ T cells and the rate of progression to AIDS in the infected monkeys. These findings
demonstrate a central role for TRIM5a in limiting the replication of an immunodeficiency virus infection in a primate host.
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Introduction
The cytoplasmic tripartite motif protein 5a (TRIM5a) has been
shown to restrict the replication of a broad range of retroviruses in
a species-specific manner [1–5]. For example, TRIM5a of rhesus
monkeys mediates an early, post-entry block of HIV-1 replication
but only a modest block of SIV replication in vitro [4], whereas
human TRIM5a restricts N-MLV potently but HIV-1 only weakly
[1–3,5]. Although primate TRIM5a variants share a similar
domain organization, TRIM5a sequences are highly polymorphic
in different species; this interspecies sequence variation of
TRIM5a is associated with differences in the viral specificity of
TRIM5a-mediated restriction [3,5,6,7]. Multiple TRIM5 alleles
have been recently identified in Old World primates, including
rhesus monkeys and sooty mangabeys [8,9]. While a few of these
polymorphic forms of TRIM5a have an effect on the susceptibility
of transduced cells to in vitro retrovirus infection (HIV-1 and N-
MLV), no significant association has been observed between any
of these TRIM5 alleles and either the control of SIV replication in
vivo or AIDS pathogenesis.
Although they are resistant to infection with HIV-1, rhesus
monkeys support the replication of certain strains of SIV and
develop an AIDS-like disease following infection with these
isolates. The SIV-infected rhesus monkey has become an
invaluable model for studying AIDS pathogenesis and evaluating
AIDS vaccine strategies [10–12]. Interestingly, high levels of viral
replication are achieved following infection with SIV in some
rhesus monkeys, whereas other rhesus monkeys appear to be more
resistant to infection. Certain MHC class I alleles have been
associated with efficient control of SIV replication in vivo on the
basis of particularly effective SIV-specific cytotoxic T lymphocyte
responses [13]. Factors other than adaptive immune responses also
have been implicated in the control of SIV replication, since the
relative permissivity of a monkey’s peripheral blood mononuclear
cells (PBMCs) for SIV replication in vitro predicts the level of SIV
replication that occurs in vivo when that monkey is infected with
SIV [14]. The present study was initiated to explore the
contribution of intraspecies TRIM5 allelic polymorphisms to the
control of SIV replication in Indian-origin rhesus monkeys.
Results
Sequencing of rhesus monkey TRIM5a
To characterize the TRIM5a variants of rhesus monkeys, full-
length TRIM5 cDNAs were derived and sequenced from 79
unrelated Indian-origin rhesus monkeys. Six to 15 independent
cDNA clones from each monkey were sequenced. Genomic DNAs
from these same animals were also sequenced to confirm the
identity of these alleles. We identified a 2-amino acid deletion and
14 single nucleotide polymorphisms (SNPs), each of which was
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(Fig. 1). The 2-amino acid deletion and most of the nonsynon-
ymous SNPs (nsSNPs) clustered in the coiled-coil (CC) and the
B30.2(SPRY) domains of the molecule. An allele was identified
with a nsSNP in the L2 linker, and 4 TRIM5 alleles were also
characterized that had synonymous polymorphisms clustered in
the CC and B30.2(SPRY) regions of the molecule. Based on the
distribution of the 10 nsSNPs, the rhesus monkey TRIM5 coding
sequences were grouped into 12 distinct alleles. These alleles and
their frequencies in a cohort of 79 monkeys are shown in Table 1,
ordered according to increasing numbers of nsSNPs. The
predicted amino acid sequence of allele 1 was identical to the
published rhesus monkey TRIM5a sequence (AY625001), and the
predicted sequence of allele 11 was most divergent from allele 1.
TRIMCyp, a molecule in which the TRIM5 RBCC domains are
fused to cyclophilin A (CypA) [15–18], was cloned from cDNAs
prepared from the rhesus monkeys and is designated as allele 12.
The coincident expression of two different alleles was observed in
many of the monkeys.
TRIM5a polymorphisms are associated with susceptibility
of B-LCLs to SIV infection
We then sought to assess the impact of this rhesus monkey
TRIM5 allelic diversity on the susceptibility of monkey cells to SIV
infection. Since TRIM5a restricts the replication of retroviruses by
interfering with a post-entry step in their life cycle, we chose first to
evaluate the effectofspecificTRIM5allelic productsbyassessingthe
invitrosusceptibilityofrhesusmonkeyB-lymphoblastoidcelllines(B-
LCLs) expressing defined TRIM5 alleles to infectionwitha vesicular
stomatitis virus G (VSV-G)-pseudotyped SIVmac239-GFP con-
struct. The relative in vitro susceptibility to SIVmac239 infection of
rhesus monkey B-LCLs expressing homozygous or heterozygous
TRIM5 alleles 1–11 is shown in Fig. 2A and B. A significant
variation in susceptibility to SIVmac239 infection was observed
among these genetically diverse B-LCLs (P=0.0164). We then used
a Dunn’s post test to compare the relative permissiveness for
infection of each group of B-LCLs to that of the B-LCLs that
expressed only TRIM5 allele 1 (Table 2). Rhesus monkey B-LCLs
homozygous for TRIM5 alleles 7, 9 and 10 were significantly more
permissive for SIVmac239 infection. The TRIM5a proteins
encoded by these alleles share identical B30.2(SPRY) domain
residues 328–497. These amino acid residues are also shared by
TRIM5a products of alleles 6, 8 and 11. Our inability to
demonstrate statistically significant increased permissiveness of
alleles 6, 8, and 11 for SIVmac239 infection may be a consequence
of the small number of B-LCL populations for evaluation. In fact,
when these B-LCLs were assigned to 3 groups on the basis of
homozygosity or heterozygosity for expression of alleles 1–5 or 6–
11, a statistically significant difference in the permissivity of the cells
for SIVmac239 infection was observed (Fig. 2C).
The observation above suggested that the permissiveness of
rhesus monkey B-LCLs for SIVmac239 replication was associated
with amino acid changes clustered in the B30.2(SPRY) domain of
TRIM5a. The TRIM5a proteins encoded by the more restricted
Author Summary
The cytoplasmic TRIM5a restricts the replication of a broad
range of retroviruses in a species-specific manner. In the
present study we show that TRIM5a is more than a species
barrier for retroviruses. We show that naturally occurring
B30.2(SPRY) polymorphisms affect retrovirus infection.
These observations demonstrate the importance of SIV/
B30.2(SPRY) interactions in vivo. These findings are the first
demonstration of the importance of such a pathogen/host
protein interaction in vivo. Importantly, the striking
variability in the clinical course of HIV-infected individuals
has long puzzled the biomedical community. A large
number of investigators have devoted considerable effort
to determine what genetically determined factors might
contribute to the containment of HIV replication, reason-
ing that an understanding of the determinants of effective
control of HIV spread will provide important targets for
both drug and vaccine development. Our demonstration
in the present study that B30.2(SPRY) polymorphisms have
a dramatic effect on the clinical outcome of an AIDS virus
infection highlight the extraordinary importance of TRIM5a
on the control of an AIDS virus infection.
Figure 1. A schematic illustrating TRIM5a and its functional domains. The major domains of TRIM5a are shaded in light grey, and the linker
1 (L1) and linker 2 (L2) regions are designated. The dark grey boxes correspond to variable regions (V1–V4) in the B30.2 (SPRY) domain of the
molecule. Locations of coding SNPs are indicated by vertical lines. Nonsynonymous (ns) SNPs with corresponding amino acid changes relative to the
major allele are shown above and synonymous SNPs are indicated below by asterisks. These alleles were defined by sequencing full-length cDNA and
genomic DNA generated from either B-lymphoblastoid cell lines (B-LCL) or PBMCs of these monkeys.
doi:10.1371/journal.ppat.1000738.g001
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B30.2(SPRY) domain. These sequences are also identical to that
previously described as rhesus monkey TRIM5a AY625001.
Interestingly, alleles 6–11 are all identical in residues 328–497 of
the B30.2(SPRY) domain, but differ from alleles 1–5 because of a
2-amino acid deletion (339–340) and 3 nsSNPs (A333S, P341Q
and S422L). The results suggest that amino acid changes in the
region including residues 328–497 of the TRIM5a B30.2(SPRY)
domain determine the efficiency of TRIM5a-mediated restriction
for SIVmac239 replication in B-LCLs.
Effects of TRIM5a polymorphisms on retrovirus infections
A number of other complementing observations were made in
studying the permissiveness of rhesus monkey B-LCLs assigned to
Table 1. TRIM5 alleles and their frequencies in Indian-origin rhesus monkeys.
TRIM5a
domain Coiled-coil L2 B30.2(SPRY)
nt Change
1 C551T T586C G664A A688G A708T A919C C979A G997T
ACGTTT1015–
1020------ C1022A C1265T
Allele
Frequency3
n/178 (%)
AA Change
2 S184L W196R E222K M230V E236D T307P P327T A333S TF339–340DD P341Q S422L
Allele 1 S W E M E T P A TF P S 59/178(33.1)
Allele 2 S W E M D T P A TF P S 8/178(4.5)
Allele 3 S W E M E P P A TF P S 8/178(4.5)
Allele 4 S W E M D P P A TF P S 9/178(5.1)
Allele 5 L R K V D T P A TF P S 13/178(7.3)
Allele 6 S R E M E T P S DD Q L 6/178(3.4)
Allele 7 S W E M E P P S DD Q L 19/178(10.7)
Allele 8 S W E M D P P S DD Q L 9/178(5.1)
Allele 9 S W E M D P T S DD Q L 9/178(5.1)
Allele 10 S W K M D P T S DD Q L 7/178(3.9)
Allele 11 L R K V D P T S DD Q L 15/178(8.4)
Allele 12
4 TRIMCyp 16/178(9.0)
1DNA sequences were aligned with the published sequence of TRIM5 of the rhesus monkey fibroblast cell line (AY625001). Nucleotide (nt) changes are shown for each
allele. Deletions are indicated by dashes.
2Predicted amino acid (AA) substitutions for nonsynonymous coding SNPs. The amino acid encoded by the predominant allele precedes the residue number, which is
followed by the amino acid encoded by the minor allele. Deletions are indicated by D.
3Frequency of TRIM5 alleles in 79 evaluated Indian-origin rhesus monkeys.
4TRIMCyp, a molecule in which the TRIM5 RBCC domain is fused to CypA [15–18], was cloned and sequenced from cDNA prepared from rhesus monkey lymphocytes.
doi:10.1371/journal.ppat.1000738.t001
Figure 2. Effect of TRIM5a variants on susceptibility of B-LCLs to SIVmac239 infection. The TRIM5 alleles expressed by selected rhesus
monkey B-LCLs were first characterized by cDNA sequencing. These B-LCLs were then evaluated for their relative susceptibility to SIVmac239
replication by incubation for 48 h with a VSV-G-pseudotyped SIVmac239-GFP construct. The percentage of cells expressing GFP was assessed by flow
cytometric analysis in B-LCLs homozygous (A) or heterozygous (B) for TRIM5 alleles 1–11. The B-LCLs were then divided into three groups: ‘‘1–5/1–5’’
expressing only TRIM5 alleles 1–5; ‘‘1–5/6–11’’ expressing a TRIM5 allele from the 1–5 groups and another from the 6–11 groups, ‘‘6–11/6–11’’
expressing only TRIM5 alleles 6–11 (C). The sequences of amino acid residues 328–479 of the TRIM5a B30.2 (SPRY) domain encoded by alleles 1–5 are
identical to each other and to those previously described as rhesus monkey TRIM5a (AY625001). In contrast, a 2-amino acid deletion (339–340) and 3
nsSNPs (A333S, P341Q and S422L) are present in the B30.2 (SPRY) domain of TRIM5a variants encoded by alleles 6–11. The comparison of the values
from the 3 groups of B-LCL was analyzed using a non-parametric one-way ANOVA Kruskal-Wallis test with a Dunn’s multiple comparison test.
doi:10.1371/journal.ppat.1000738.g002
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or 6–11 to retrovirus infection. We found that B-LCLs expressing
only TRIM5 alleles 1–5 efficiently restricted SIVsmE543 and
HIV-1 infection, whereas B-LCLs expressing only TRIM5a
molecule from the group of alleles 6–11 were more permissive
for infection by these virus constructs (Fig. 3A, B). The overall
infectivity of HIV-1 was substantially lower than that of
SIVmac239 in the rhesus monkey B-LCLs. This likely reflects
the fact that, even in B-LCLs bearing alleles 6–11, rhesus monkey
TRIM5a provides a significant barrier to HIV-1 infection. In
contrast to this finding, no significant differences in susceptibility to
infection by other retroviruses such as equine infectious anemia
virus (EIAV), feline immunodeficiency virus (FIV), N-tropic
murine leukemia virus (N-MLV) and B-tropic murine leukemia
virus (B-MLV) were found between B-LCLs expressing one or the
other groups of TRIM5 alleles (Fig. 3C–F). These results suggest
the rhesus monkey TRIM5a polymorphisms specifically influence
restriction potency for a subset of retroviruses that includes the
primate immunodeficiency viruses (PIVs).
TRIM5 allelic variants differ in their ability to restrict VSV-
G-pseudotyped SIVmac239-GFP infection of feline
fibroblasts
The contribution of specific rhesus monkey TRIM5 alleles to the
inhibition of SIVmac infection was also assessed in TRIM5-
transduced cell lines. Feline renal fibroblast (CRFK) cells were
stably transduced to express TRIM5a variants encoded by alleles
1, 5, 7 or 11. To produce recombinant viruses, we co-transfected
293T cells with the pLPCX vectors expressing each TRIM5a
variant with pVpack-GP and pVPack-VSV-G packaging plasmids.
CRFK cells were transduced using the resulting viruses and then
selected in G418. These transduced cells were infected with a
VSV-G-pseudotyped SIVmac239-GFP construct and subjected to
flow cytometric analysis. Consistent with the studies of the B-
LCLs, we found that cells transduced with allele 1 or 5 supported a
lower level of infection by SIVmac239-GFP, whereas cells
transduced with allele 7 or 11 supported a higher level of
SIVmac239 infection (Fig. 4A). We also assessed the infectivity of
VSV-G-pseudotyped GFP-expressing SIVsmE543, HIV-1, EIAV,
FIV, N-MLV and B-MLV viruses these same transduced cells.
The restriction of SIVsmE543 and HIV-1 infection was more
efficient in cells transduced with allele 1 or 5 than in cells
transduced with allele 7 or 11 (Fig. 4A). While transduction of cells
with the TRIM5 alleles inhibited infection by EIAV, FIV and N-
MLV, all evaluated TRIM5 alleles inhibited the infection with
comparable efficiency (Fig. 4B). Expression of these alleles did not
restrict B-MLV infection (Fig. 4B). We verified that the HA
epitope tag at the C terminus of the TRIM5a protein did not
affect the ability of transduced cells to restrict SIVmac239
infection (data not shown). We also confirmed that downregulation
of TRIM5a expression by siRNA specifically rescued the
infectivity of the restricted SIVmac239 (data not shown). Since
the level of TRIM5a protein expression in each of the transduced
cells was comparable as determined by Western blotting,
differences in TRIM5a protein expression level could not account
for the observed differences in the ability of the cells to restrict
SIVmac239 infection. The TRIM5a proteins encoded by allele 1
and 7, and by alleles 5 and 11, differ only in the sequences of the
B30.2(SPRY) domain (Table 1). Therefore, as in the studies of B-
LCLs, the permissiveness for SIVmac replication in the transduced
cells was associated with amino acid changes clustered in the
B30.2(SPRY) domain of TRIM5a.
Effects of TRIM5a polymorphisms on SIVmac239 capsid
binding
We then explored the mechanism accounting for the
differences in efficiency of restriction of SIVmac239 infection
mediated by these different TRIM5 alleles. A direct interaction
of TRIM5a with the retroviral capsid is required for restriction
of retrovirus replication [19–21]. The recognition of the capsid
by TRIM5a is mediated by the B30.2(SPRY) domain. Because
the phenotypic differences among rhesus monkey TRIM5a
variants grouped according to the sequence of the B30.2(SPRY)
domain, we hypothesized that the two groups of TRIM5a
variants might exhibit differences in the ability to bind SIVmac
capsids. Two TRIM5a proteins encoded by alleles 1 and 7 were
studied for capsid-binding ability. TRIM5 allele 1 represents the
major allele and encodes a protein identical in sequence to that
of the previously reported rhesus monkey TRIM5a [4]. The
TRIM5a protein encoded by allele 7 differs from that encoded
by allele 1 only in the sequence of the B30.2(SPRY) domain
(Table 1). Therefore, TRIM5a variants 1 and 7 were chosen as
representatives of the two groups of TRIM5a B30.2(SPRY)
Table 2. Comparison of the % GFP values from rhesus
monkey B-LCLs expressing various combinations of TRIM5
alleles with a control group of B-LCLs expressing only the
TRIM5 allele 1.
TRIM5 alleles n Difference in rank sum P value Significant
Homozygous
2 2 2 0.963 1.000 No
332 21.137 1.000 No
4 4 3 3.467 1.000 No
553 25.903 0.986 No
662 211.887 0.491 No
772 219.587 0.025 Yes
882 211.042 0.604 No
993 222.537 0.006 Yes
10 10 2 217.603 0.018 Yes
11 11 3 210.270 0.494 No
Heterozygous
1 2 2 4.983 0.998 No
133 22.890 1.000 No
1 4 3 1.907 1.000 No
152 23.852 1.000 No
162 212.887 0.368 No
173 214.437 0.092 No
183 211.277 0.353 No
192 213.187 0.335 No
11 0 2 210.932 0.619 No
11 1 2 211.307 0.568 No
2 3 1 0.773 1.000 No
2 5 1 3.763 1.000 No
5 10 1 3.243 1.000 No
581 29.937 0.964 No
91 1 1 27.137 0.999 No
Dunn’s multiple comparison test was applied to assess the significance of the
difference in GFP expression between each of the groups of B-LCLs and the
TRIM5 allele 1 homozygous B-LCLs.
doi:10.1371/journal.ppat.1000738.t002
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capsid.
For this purpose, we adapted an in vitro capsid-binding assay,
which has been used to study TRIM5a binding to the HIV-1
capsid [22]. In our assay, SIVmac239 capsid-nucleocapsid (CA-
NC) complexes were generated in vitro, and then incubated with
serial dilutions of 293T cell lysates containing TRIM5a allelic
variants 1 and 7. After incubation, TRIM5a protein bound to CA-
NC complexes was separated from unbound TRIM5a by pelleting
through a sucrose cushion. The amount of TRIM5a in both input
and pellet was analyzed by Western blotting and densitometry. As
expected from previous experience with the HIV-1 capsid-
nucleocapsid binding assay [23], both TRIM5a allelic variants
bound the SIVmac239 CA-NC complexes in a dose-dependent
manner with a sigmoidal pattern. Importantly, however, binding
of the variant encoded by TRIM5 allele 7 was less efficient than
that of the TRIM5a allele 1 variant (Fig. 5A, B). This finding is
consistent with the possibility that differences in the efficiency of
binding the SIVmac239 capsid contribute to the observed
differences in SIVmac239 restriction potency, with the less
efficiently binding allelic variant 7 mediating the less potent
restriction of viral replication.
TRIM5a polymorphisms are associated with plasma viral
RNA levels and clinical sequelae of SIVmac251 infection
To determine the ramifications of these in vitro findings for the
control of viral replication in vivo, a study was done to determine
whether the expression of particular TRIM5 alleles by Indian-
origin rhesus monkeys was associated with the in vivo control of
SIVmac251 replication. We tested the specific hypothesis that
variation in residues 328–497 of the TRIM5a B30.2(SPRY)
domain influences the course of SIVmac251 infection in vivo. The
monkeys were divided into 3 groups: in one group, only TRIM5
alleles 1–5 were expressed; in the second group, one copy of alleles
1–5 and one copy of alleles 6–11 were expressed; and in the third
group, only alleles 6–11 were expressed. Monkeys were selected
for this study that did not express the MHC class I alleles Mamu-
A*01, -B*08, or -B*17, as their expression is associated with
particularly efficient control of SIV replication [24–26]. Eliminat-
ing these monkeys from the evaluated animals eliminated an
already defined source of variation in virus control.
Plasma SIV RNA levels were assessed in this cohort of rhesus
monkeys through day 178 after SIVmac251 challenge. We
measured viral replication for each monkey by doing an area-
under-the curve calculation for the plasma SIV RNA levels
between days 1 and 70 following infection. A 0.1 log median
difference in these values was observed between the allele 1–5
homozygous and the allele 1–5/allele 6–11 heterozygous monkeys,
and a 0.6 log median difference in these values was observed
between the allele 1–5 homozygous and the allele 6–11
homozygous monkeys (Fig. 6A). Plasma virus RNA levels were
also assessed in this cohort of rhesus monkeys on days 14 (peak)
and 70 (set-point) following the intravenous inoculation of
SIVmac251. Consistent with the decreased in vitro antiviral activity
of the products of TRIM5 alleles 6–11, the expression of TRIM5
alleles 6–11 by the rhesus monkeys was associated with higher
levels of SIVmac251 replication in vivo. A 0.4 log median
difference in plasma virus RNA levels at the time of peak viral
replication was observed between the allele 1–5 homozygous and
the allele 1–5/allele 6–11 heterozygous monkeys, and a 0.6 log
Figure 3. Effects of TRIM5a variants on susceptibility of rhesus monkey B-LCLs to VSV-G-pseudotyped retrovirus constructs. Rhesus
monkey B-LCLs expressing selected TRIM5 alleles were divided into two groups, one expressing only TRIM5 alleles 1–5, and the other expressing only
TRIM5 alleles 6–11. They were then evaluated for their relative susceptibility to retrovirus infection by incubation for 48 h with VSV-G-pseudotyped
recombinant SIVsmE543-GFP (A), HIV-1-GFP (B), EIAV-GFP (C), FIV-GFP (D), N-MLV-GFP (E) or B-MLV-GFP (F) and assessed for % of cells expressing GFP
by flow cytometric analysis. The comparison of the values from the 2 groups of B-LCL was analyzed using the Mann-Whitney test.
doi:10.1371/journal.ppat.1000738.g003
TRIM5a Modulates SIV Control in Rhesus Monkeys
PLoS Pathogens | www.plospathogens.org 5 January 2010 | Volume 6 | Issue 1 | e1000738median difference in these values was observed between the allele
1–5 homozygous and the allele 6–11 homozygous monkeys
(Fig. 6A). A log median difference in set-point virus RNA levels
was 0.7 between the allele 1–5 homozygous and the allele 1–5/
allele 6–11 heterozygous monkeys, and 1.3 between the allele 1–5
homozygous and the allele 6–11 homozygous monkeys (Fig. 6A).
We then assessed the clinical consequences of infection in these
monkeys. First, we evaluated the loss of peripheral blood total
CD4+ T cells and CM CD4+ T cells in the monkeys following
SIVmac251 inoculation. We sought to determine whether the
expression of particular TRIM5 alleles was associated with
particular immune sequelae of infection. We displayed the data
in two ways: dividing the monkeys into 3 cohorts as described
above and dividing the monkeys into 2 cohorts, one group of
animals expressing only alleles 1–5 and the other expressing at
least 1 allele of the group 6–11. The expression of TRIM5 alleles
6–11 by the rhesus monkeys was associated with a rapid loss of
both total CD4+ T cells and CM CD4+ T cells (Fig. 6B). Then we
assessed the effect of the expression of TRIM5 alleles 6–11 on the
survival of the monkeys following infection (log-rank test of
equality, Kaplan-Meyer survival curves). The monkeys expressing
only alleles 1–5 maintained a statistically significant survival
advantage over the monkeys expressing at least 1 allele of the
group 6–11 (Fig. 6C). Therefore, the expression of TRIM5 alleles
6–11 was associated with both less efficient control of SIVmac
replication in vivo and an increased rate of disease progression.
Discussion
We demonstrated TRIM5 allele-determined relative resistance
to SIV infection in vitro using both B-LCL and transduced
fibroblast target cells. However, the variable resistance or
permissiveness for infection was more readily apparent in the B-
LCL than in the fibroblasts. This difference between target cell
populations may reflect differences in TRIM5 expression under
normal physiologic control in B-LCLs and in transduced CRFK
cells. Thus, overexpression in CRFK cells may partially mask the
relative inefficiency of some of the TRIM5 alleles to restrict SIV
and HIV replication in vitro.
A number of genes have previously been implicated in the
control of HIV-1 replication. These include selected MHC class I
alleles and loci, including HLA B*5701, HLA B*27 [27] and HLA
C [28], as well as HLA Bw4-8OI in association with KIR3DS1
[29]. Expression of an allelic form of the HIV-1 co-receptor, the
delta 32 form of CCR5, is also associated with HIV-1 containment
[30–32]. These genes and gene loci are thought to contribute to
HIV-1 control through classical immune effector mechanisms or
viral entry.
Figure 4. Antiretroviral activity of TRIM5a variants expressed in feline renal fibroblast (CRFK) cells. Feline renal fibroblast (CRFK) cells
stably expressing TRIM5a variants encoded by allele 1, 5, 7 or 11, or control cells transduced with the empty pLPCX vector were incubated with a VSV-
G-pseudotyped recombinant virus construct for 48 h and then subjected to flow cytometric analysis. (A) To assess the effects of TRIM5a variants on
the infection of primate immunodeficiency viruses (PIVs), SIVmac239-GFP, SIVsmE543-GFP, and HIV-1-GFP were tested. The results of a repeat
experiment are shown. Six dilutions of the stock of SIVmac239-GFP, SIVsmE543-GFP, and HIV-1-GFP were used to infect the transduced cell lines. (B)
CRFK cells expressing different TRIM5a variants or control cells transduced with the empty pLPCX vector were incubated with EIAV-GFP, FIV-GFP, N-
MLV-GFP or B-MLV-GFP. Infected GFP-positive cells were assessed by flow cytometric analysis. Represent data from repeated experiments are shown.
Six dilutions of EIAV-GFP, FIV-GFP, N-MLV-GFP, and B-MLV-GFP were used to achieve 100% transduction of the control cells with the empty pLPCX
vector. (C) The expression of TRIM5a protein by the transduced cells was determined by Western blotting using an anti-HA antibody. Levels of b-actin
were also assessed as a control for the loading of total protein.
doi:10.1371/journal.ppat.1000738.g004
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B30.2(SPRY) polymorphisms affect immunodeficiency virus
infections. These observations demonstrate the importance of
SIV/B30.2(SPRY) interactions in vivo. The finding that TRIM5
allelic products are associated with both the permissiveness of cells
to HIV-1/SIV infection in vitro and clinical sequelae of SIV
infection in vivo expands the known genetic determinants of HIV-
1/SIV susceptibility and implicates a novel intracellular mecha-
nism in that virus control.
Our data suggest that the co-expression of restrictive and
permissive TRIM5a variants results in a less effective antiretroviral
state than the expression of two restrictive TRIM5a variants.
Differences in SIVmac restriction potency and capsid binding map
to the B30.2(SPRY) domain of the rhesus monkey TRIM5a
variants. As the functional TRIM5a moiety is thought to an
oligomer [33–36], co-expression of TRIM5a variants with
different capsid-binding affinities would be expected to result in
heterodimers with decreased avidity for the capsid. Dominant-
negative effects of less functional TRIM5a variants on more
potently restricting TRIM5a variants have been observed
[4,37–39].
A number of groups have evaluated the contribution of
common TRIM5a polymorphisms to AIDS susceptibility in
HIV-1-infected humans [40–44]. These various studies have
defined associations of nsSNPs in the RING, B-box 2, Coiled-coil
domains and Linker 2 region of the molecule with very modest
effects on HIV-1 susceptibility and AIDS clinical progression [40–
43]. The single SPRY domain ns SNP in human TRIM5a,
H419Y, was also shown to have only a modest effect on these
clinical endpoints [44]. The absence of evidence for a robust
association between a SNP in TRIM5a and a substantial HIV-1-
associated clinical endpoint in humans is likely a consequence of
the fact that the common variant forms of this molecule in humans
do not have severely impaired interactions with retroviruses. The
human TRIM5 SNPs are for the most part clustered in the B-box 2
and Coiled-coil domains of the molecule, regions of TRIM5a that
are not thought to contact the retrovirus capsid. In contrast, as we
have shown in the present study, variants of TRIM5a in the rhesus
monkey that cluster in the B30.2 (SPRY) domain of the molecule
have a significant impact on the interaction of TRIM5a with the
capsid of SIV and, as a result, exert a significant effect on SIV
replication in vitro and in vivo.
The findings in the present study indicate that TRIM5a has a
function beyond restricting cross-species transmission of retrovi-
ruses. We show that TRIM5a variants with an impaired ability to
interact with the retrovirus capsid restrict pathogenic retroviruses
in a susceptible host species less efficiently both in vitro and in vivo.
Therefore, TRIM5a proteins can exert antiretroviral effects
Figure 5. Effect of TRIM5a variation on SIVmac239 capsid binding. Serial dilutions of 293T cell lysates (input) containing TRIM5a-HA proteins
encoded by allele 1 or allele 7 were incubated with equal amounts of SIVmac239 CA-NC complexes assembled in vitro. After incubation, the mixtures
were pelleted through a sucrose cushion. The amounts of TRIM5a in both input and pellet were subjected to Western blotting and densitometry. The
results of two separate experiments are shown. The Western blot (A) of experiment 1 was quantitatively analyzed by a densitometer with the results
shown in (B). The last two samples of the allele 7 variant were beyond the linear range of the densitometry and, therefore, were not included in the
final analysis in (B). Both pellet and input amounts are shown in arbitrary densitometric units.
doi:10.1371/journal.ppat.1000738.g005
TRIM5a Modulates SIV Control in Rhesus Monkeys
PLoS Pathogens | www.plospathogens.org 7 January 2010 | Volume 6 | Issue 1 | e1000738Figure 6. Association of the expression of groups of TRIM5 alleles by rhesus monkeys with viral replication following SIVmac251
infection. (A) Plasma virus RNA levels were assessed in a cohort of Indian-origin rhesus monkeys between days 1 and 178 after challenge. Area-
under-the curve calculations for the plasma SIV RNA levels were assessed in these monkeys. The plasma SIV RNA levels were also assessed on days 14
and 70 following challenge, representing peak and set-point viral load, respectively. (B) The loss of total CD4+ T cells and central memory CD4+ T cells
was monitored in the same cohorts of rhesus monkeys following SIVmac251 infection. Data are displayed two ways: dividing the monkeys into 3
cohorts as described in the legend to Fig. 2 or dividing the monkeys into 2 cohorts, one of animlas expressing only alleles 1–5 and the other of
animals expressing at least 1 allele of the groups 6–11. (C) The survival of monkeys following SIVmac251 infection is shown in Kaplan-Meier (KM)
curves. The P-value corresponds to the log-rank test of equality of the survival curves. The monkeys are divided into either 3 or 2 groups as described
above. The comparison of the values from the groups of monkeys was analyzed using a non-parametric one-way ANOVA Kruskal-Wallis test with
Dunn’s multiple comparison test or the Mann-Whitney test.
doi:10.1371/journal.ppat.1000738.g006
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infection.
Methods
Cells
HEK293T and feline renal fibroblasts (CRFK) were obtained
from American Type Culture Collection and grown in RPMI/
10% FBS.
Recombinant viruses
Recombinant SIVmac239-GFP virus was produced by
cotransfection of HEK293T cells with pSIVmac239Denv-
GFP, pVSV-G and pRev using the Lipofectamine 2000
(Invitrogen). HIV-1-GFP, SIVsmE543-GFP, EIAV-GFP, FIV-
GFP, B- and N-MLV-GFP viruses were prepared as previously
described [7]. At 48h after transfection, cell-free supernatant
was collected. The titer of virus in the supernatant was
determined by infection of HEK293T cells and assessment for
% of cells expressing GFP by flow cytometric analysis. An SIV
p27 antigen ELISA was performed to measure the p27 gag gene
product of SIV.
Establishment of B Lymphoblastoid Cell Lines (B-LCLs)
B-LCLs were generated from the same cohort of 28 uninfected
rhesus monkeys and 32 rhesus monkeys previously infected with
SIVmac251 as described [45]. Briefly, B cells were transformed by
incubating peripheral blood mononuclear cells isolated from
rhesus monkeys with Herpesvirus papio. B-LCLs were then
propagated in RPMI 1640 supplemented with 20% FBS and
penicillin-streptomycin.
Sequencing of TRIM5a cDNA
Total RNA was isolated from H. papio-immortalized rhesus
monkey B-LCLs and PBMCs by using the RNeasy Mini kit (Qiagen).
Untagged, full-length TRIM5a cDNAcloneswere generated by RT-
PCR with primers TRIM5F1 (59-CAGACGAATTCCAC-
CATGGCTTCTGGAATCCTG-39)a n dT R I M 5 R 1( 5 9-GGA-
CGTTCGAAATAGAAAGAAGGGAGACAGC-39)b yu s i n gt h e
SuperScript One-Step kit (Invitrogen). PCR products were cloned
directly into the TOPO Blunt vector (Invitrogen). Six to 15
independent cDNA clones from individual rhesus monkeys were
subjected to automated sequence analysis (GENEWIZ). Genomic
DNA was isolated from lymphocytes from the same cohorts of rhesus
monkeys by using QIAamp DNA kit (Qiagen), and sequenced.
Primer selection was facilitated by the use of the computer program
Beacon 3. Primer sequences used to amplify and sequence TRIM5
exons or TRIM5 cDNAs are shown in Table S1. To generate
TRIM5a C-terminally tagged with hemagglutinin (HA), genes were
amplified with primers TRIM5F1 and TRIM5HA-R (59-
CCACCGGTGGCTCAAGCGTAGTCTGGGACGTCGTATG-
GGTAGCCGCCAGAGCTTGGTGAGCACAGAG-39).
Rhesus monkey B-LCL infection
B-LCLs were selected for study that had previously defined
TRIM5 alleles. A VSV-G pseudotyped recombinant virus
constructs were used for single-round infection. 4610
4 cells per
well were seeded into 96-well plates and cells were infected with
serial dilutions of virus by spinoculation for 2 h at 1,9006g. At
48 h after infection, these B-LCLs were evaluated for their
relative susceptibility to retrovirus replication by assessing for the
% of cells expressing GFP as determined by flow cytometric
analysis.
Restriction in CRFK cells expressing TRIM5 alleles
Feline renal fibroblast (CRFK) cells stably expressing TRIM5a
variants encoded by allele 1, 5, 7 or 11 were generated as
described by Stremlau et al. [4]. Briefly, 293T cells were co-
transfected with the pLPCX vectors containing each TRIM5a
cDNA with pVpack-GP and pVPack-VSV-G packaging plasmids
(Stratagene) to produce recombinant viruses. CRFK cells were
then transduced using the resulting viruses and selected in G418
(0.5mg/ml, Sigma-aldrich). For infection, CRFK cells expressing
TRIM5a variants encoded by allele 1, 5, 7 or 11, or control cells
transduced with the empty pLPCX vector were harvested and
subsequently seeded into 48-well plates (1.2610
4 cells per well).
Cells were incubated with a VSV-G-pseudotyped recombinant
virus construct for 48 h and then subjected to flow cytometric
analysis.
Immunoblotting
Feline renal fibroblast (CRFK) cells were transduced as
described above and harvested. Cells were then lysed in NP-40
lysis buffer (Boston BioProducts). Total protein was measured by
using a BCA assay kit (Pierce) and equal amounts (20 mg) were
separated by SDS/PAGE. HA-tagged TRIM5a was detected with
either monoclonal anti-HA antibody (Roche) and HRP-conjugat-
ed either anti-rat or anti-rabbit IgG secondary antibody,
respectively (Sigma-Aldrich). Levels of b-actin were also assessed
as a control for the loading of total protein by using anti-b-actin
antibody (Sigma-Aldrich).
Capsid-binding assay
The SIVmac239 CA-NC fusion protein was expressed in
Escherichia coli and purified with minor modifications from the
previously described purification method used for the HIV-1 CA-
NC protein [22]. The purified SIVmac CA-NC protein was mixed
with (TG)
50 DNA oligonucleotides in 50 mM Tris-HCl (pH 7.0)
and 500 mM NaCl solution and incubated at 37uC. The resulting
SIVmac CA-NC complexes were negatively stained and examined
under the electron microscope, confirming that the size and shape
of the CA-NC complexes are very similar to those HIV-1 CA-NC
complexes.
Approximately 1610
7 293T cells were transiently transfected to
express the appropriate TRIM5 allele or with a control vector, and
then harvested at 24 h post-transfection. The cells were lysed in
1 ml of hypotonic lysis buffer (10 mM Tris-HCl, pH 7.0/10 mM
KCl). After brief centrifugation at 4uC to remove cell debris, the
supernatant was spun at 110, 0006g for 1 h at 4uC in a Beckman
ultracentrifuge. After the pre-cleaning spin, different amounts of
the supernatants containing the TRIM5a variants were aliquoted
in separate tubes and were complemented with the supernatants
from the vector-transformed cells to achieve a final volume of
200 ml. To these mixtures, the same amount of SIVmac CA-NC
complexes were added and the final concentration of NaCl was
adjusted to 200 mM before incubation at 30uC for 1 h. After
incubation, 20 ml of the mixtures were saved for further analysis as
an input and the rest of mixtures were layered onto 60% sucrose
cushion (prepared in 16 PBS) and centrifuged at 110,0006g for
1 h at 4uC in a Beckman ultracentrifuge. The pellet was
resuspended in 16 SDS sample buffer and subjected to SDS/
PAGE and Western blotting.
Monoclonal antibody (MAb) staining of cell surface
molecules and CD4+ T-lymphocyte counts
Peripheral blood mononuclear cells (PBMCs) were stained with
MAbs specific for cell surface molecules, including CD3, CD4,
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Peripheral blood CD4+ T lymphocyte and central memory CD4+
T lymphocyte counts were calculated by multiplying the total
lymphocytes count by the percentage of CD3+CD4+ T cells, and
CD95+CD28+ T cells, respectively, determined by MAb staining
and flow cytometric analysis [46].
In vivo infection
Animals. Indian-origin rhesus monkeys used in the analysis
were maintained according to the guidelines of the NIH Guide to the
Care and Use of Laboratory Animals and the approval of the
Institutional Animal Care and Use Committee of Harvard
Medical School and the National Institute of Health.
Challenge virus. A stock of uncloned SIVmac251 was
expanded on human PBMC and titered in vivo in rhesus
monkeys for use in intravenous challenge studies [47]. All
monkeys used in the retrospective analysis were received 1 ml of
a 1:3000 dilution of this stock by intravenous route.
Plasma viral RNA assay. Assays were performed using an
ultrasensitive branched DNA amplification assay (Bayer
Diagnostics).
Statistical analysis
The two-sided nonparametric Mann-Whitney test was used to
determine statistical significance. Levels of P ,0.05 were
considered statistically significant. For multiple comparisons,
non-parametric one-way ANOVA Kruskal-Wallis test was used
with Dunn’s multiple comparison test.
Supporting Information
Table S1 TRIM5a sequencing primers used in the study
Found at: doi:10.1371/journal.ppat.1000738.s001 (0.05 MB PDF)
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